A Phase 2 interventional study of Nivolumab and BCG in Urinary Bladder Neoplasms, sponsored by Bristol-Myers Squibb. Terminated at 88 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-01.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.
Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 29th largest by enrollment of the 93 interventional ones that give a count, is one of 5 that started in 2018, is one of 20 in phase 2, and was the 31st registered.
294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.
Browse Non-Muscle Invasive Bladder Neoplasms studies →39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. · Sites in United States
Ages 18+
Natera, Inc. · Sites in United States
Ages 18+
Janssen Research & Development, LLC · Sites in United States
Ages 18+
Protara Therapeutics · Sites in United States, Ukraine
Ages 18+
Michael A. O'Donnell · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 42 · Phase 3 27 · Phase 4 1
First in 2005; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 62 across 231 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.
Median enrollment 55 across the 93 interventional studies, 408 across the 19 observational. Of the 46 that completed or were terminated, 25 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 114 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 1 study filed under Non-Muscle Invasive Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
13 of the studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111235Phase 3CG Oncology, Inc.A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | 2026-11 |
| NCT05544552Tyra Biosciences, IncSafety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | 2026-11 |
| NCT06173349University of California, DavisPLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer | 2026-12 |
| NCT03945162Theralase® Technologies Inc.Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients | 2026-12 |
| NCT04375813Robert SvatekTrial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.
This study's enrollment of 142 is above the median of 62 across 231 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.
Browse Non-Muscle Invasive Bladder Neoplasms studies →Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Bladder Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab
Biological: Nivolumab · Biological: BCG
Biological: Nivolumab · Drug: BMS-986205
Biological: Nivolumab · Biological: BCG · Drug: BMS-986205
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Bacillus Calumette-Guerin
Specified dose on specified days
Number of Participants With Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Number of Participants With Serious Adverse Events (SAEs)
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization. SAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Treatment
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs leading to discontinuation are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Number of Participants Immune-Mediated Adverse Events (IMAEs)
IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity IMAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Number of Participants Who Died
Number of participants who died.
Time frame: From first dose to 100 days post last dose of study treatment (an average of 45 weeks up to approximately 74 weeks)
Number of Participants With Specific Liver Laboratory Abnormalities
On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal.
Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Number of Participants With Specific Thyroid Laboratory Abnormalities
On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal
Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Number of Participants With Changes From Baseline Laboratory Values
On-study laboratory parameters include hematology, chemistry, liver function, and renal function. On-study laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. On-study lab parameters are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: From baseline to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Number of Participants With Adverse Events (AEs) by Anti-Drug- Antibody (ADA) Status
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug. An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.
Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Number of Participants With Serious Adverse Events (SAEs) by Anti-Drug- Antibody (ADA) Status
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization. An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug. An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.
Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
| Milestone | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| Started | 16 | 26 | 17 | 10 |
| Safety-lead in phase | 0 | 10 | 0 | 10 |
| Completed | 6 | 15 | 2 | 3 |
| Not completed | 10 | 11 | 15 | 7 |
| Withdrew: Disease recurrence | 4 | 4 | 5 | 2 |
| Withdrew: Study drug toxicity | 0 | 2 | 5 | 2 |
| Withdrew: Adverse event unrelated to study drug | 0 | 1 | 1 | 0 |
| Withdrew: Participant request to discontinue study treatment | 0 | 0 | 0 | 2 |
| Withdrew: Other reasons | 0 | 0 | 2 | 0 |
| Withdrew: Disease progression | 6 | 3 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 15 | 26 | 15 | 10 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization. SAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 2 | 4 | 6 | 4 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs leading to discontinuation are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Treatment | 1 | 4 | 8 | 7 |
IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity IMAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| Number of Participants Immune-Mediated Adverse Events (IMAEs) | 1 | 10 | 6 | 5 |
Number of participants who died.
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| Number of Participants Who Died | 0 | 3 | 2 | 0 |
On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal.
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| ALT OR AST > 3XULN | 0 | 1 | 7 | 2 |
| ALT OR AST> 5XULN | 0 | 0 | 5 | 1 |
| ALT OR AST> 10XULN | 0 | 0 | 1 | 1 |
| ALT OR AST > 20XULN | 0 | 0 | 1 | 0 |
| TOTAL BILIRUBIN > 2XULN | 0 | 0 | 1 | 1 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 1 DAY | 0 | 0 | 1 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 30 DAYs | 0 | 0 | 1 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 0 | 0 | 1 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS | 0 | 0 | 1 | 0 |
| ALP>1.5XULN | 0 | 2 | 1 | 0 |
On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| TSH > ULN | 5 | 5 | 2 | 1 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 4 | 5 | 1 | 1 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 2 | 1 | 2 | 0 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 2 | 3 | 1 | 0 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 2 | 3 | 0 | 1 |
| TSH < LLN | 2 | 3 | 3 | 1 |
| TSH <LLN WITH TSH >= LLN AT BASELINE | 2 | 3 | 3 | 1 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 2 | 1 | 1 | 1 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 1 | 3 | 0 | 0 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 0 | 0 | 2 | 0 |
On-study laboratory parameters include hematology, chemistry, liver function, and renal function. On-study laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. On-study lab parameters are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| Hemoglobin | 1 | 7 | 5 | 6 |
| Platelet Count | 1 | 1 | 1 | 1 |
| Leukocytes, Local Lab | 0 | 0 | 4 | 0 |
| Lymphocytes (Absolute) | 0 | 0 | 3 | 0 |
| Lymphocytes (Absolute), Local Lab | 2 | 7 | 2 | 5 |
| Absolute Neutrophil Count | 0 | 1 | 1 | 0 |
| Alkaline Phosphatase (ALP), Local Lab | 0 | 2 | 2 | 1 |
| Aspartate Aminotransferase (AST), Local Lab | 3 | 5 | 12 | 3 |
| Alanine Aminotransferase (ALT), Local Lab | 4 | 10 | 13 | 7 |
| Bilirubin Total, Local Lab | 1 | 2 | 5 | 3 |
| Creatinine, Local Lab | 1 | 8 | 3 | 5 |
| Hypernatremia | 0 | 3 | 4 | 2 |
| Hyponatremia | 4 | 3 | 4 | 3 |
| Hyperkalemia | 0 | 3 | 2 | 3 |
| Hypokalemia | 2 | 2 | 1 | 1 |
| Hypercalcemia | 2 | 4 | 0 | 3 |
| Hypocalcemia | 0 | 1 | 2 | 2 |
| Hypermagnesemia | 3 | 1 | 2 | 0 |
| Hypomagnesemia | 1 | 3 | 1 | 3 |
| Hyperglycemia | 4 | 1 | 3 | 1 |
| Hypoglycemia | 0 | 1 | 1 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug. An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| Nivolumab ADA Positive | — | 1 | 1 | — |
| Nivolumab ADA Negative | 11 | 21 | 11 | 9 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization. An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug. An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.
| Participants | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| Nivolumab ADA Positive | 0 | 1 | 0 | 0 |
| Nivolumab ADA Negative | 1 | 3 | 4 | 4 |
Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 48 months). SAEs and Other AEs were assessed from first dose to 100 days after last dose of study therapy (an average of 45 weeks up to approximately 74 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Nivolumab | 0/16 (0%) | 4/16 (25%) | 15/16 (93.8%) |
| Arm B: Nivolumab Plus Intravesical BCG | 3/26 (11.5%) | 7/26 (26.9%) | 26/26 (100%) |
| Arm C: Nivolumab Plus BMS-986205 | 2/17 (11.8%) | 7/17 (41.2%) | 15/17 (88.2%) |
| Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Event | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| HaematuriaRenal and urinary disorders | 0/16 | 0/26 | 0/17 | 2/10 |
| Bladder cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/16 | 0/26 | 1/17 | 1/10 |
| Retroperitoneal haemorrhageGastrointestinal disorders | 0/16 | 0/26 | 0/17 | 1/10 |
| Bile duct stoneHepatobiliary disorders | 0/16 | 0/26 | 0/17 | 1/10 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/16 | 0/26 | 0/17 | 1/10 |
| HyponatraemiaMetabolism and nutrition disorders | 0/16 | 0/26 | 0/17 | 1/10 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/16 | 0/26 | 1/17 | 1/10 |
| HypotensionVascular disorders | 0/16 | 0/26 | 0/17 | 1/10 |
| DiarrhoeaGastrointestinal disorders | 1/16 | 0/26 | 0/17 | 0/10 |
| SepsisInfections and infestations | 1/16 | 0/26 | 0/17 | 0/10 |
| Event | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG |
|---|---|---|---|---|
| PollakiuriaRenal and urinary disorders | 2/16 | 8/26 | 1/17 | 7/10 |
| Influenza like illnessGeneral disorders | 0/16 | 1/26 | 0/17 | 5/10 |
| HaematuriaRenal and urinary disorders | 4/16 | 11/26 | 4/17 | 5/10 |
| FatigueGeneral disorders | 3/16 | 9/26 | 3/17 | 4/10 |
| Alanine aminotransferase increasedInvestigations | 1/16 | 2/26 | 4/17 | 4/10 |
| Aspartate aminotransferase increasedInvestigations | 0/16 | 1/26 | 5/17 | 4/10 |
| Blood creatinine increasedInvestigations | 0/16 | 1/26 | 0/17 | 4/10 |
| DysuriaRenal and urinary disorders | 0/16 | 10/26 | 1/17 | 4/10 |
| Micturition urgencyRenal and urinary disorders | 0/16 | 7/26 | 0/17 | 4/10 |
| Urinary tract infectionInfections and infestations | 1/16 | 9/26 | 2/17 | 3/10 |
| Age, Continuous(Years) | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG | Total |
|---|---|---|---|---|---|
| Mean | 61.8 ± 11.1 | 69.0 ± 9.4 | 69.1 ± 12.3 | 69.9 ± 16.4 | 67.5 ± 11.8 |
| Sex: Female, Male(Participants) | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG | Total |
|---|---|---|---|---|---|
| Female | 2 | 4 | 5 | 1 | 12 |
| Male | 14 | 22 | 12 | 9 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 3 | 1 | 6 |
| Not Hispanic or Latino | 11 | 23 | 8 | 9 | 51 |
| Unknown or Not Reported | 5 | 1 | 6 | 0 | 12 |
| Race/Ethnicity, Customized(Participants) | Arm A: Nivolumab | Arm B: Nivolumab Plus Intravesical BCG | Arm C: Nivolumab Plus BMS-986205 | Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG | Total |
|---|---|---|---|---|---|
| White | 13 | 26 | 17 | 10 | 66 |
| Asian | 3 | 0 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Aug 2022, 48 months.
Results were first posted in Jun 2023, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Non-Muscle Invasive Bladder Neoplasms →